Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Promacta, Doribax Applications Get Advisory Committee Reviews

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen’s Enbrel will also be reviewed for a pediatric psoriasis indication.

You may also be interested in...



FDA Notes Theoretical Cancer Risk For Centocor’s Ustekinumab

MAb for psoriasis has favorable odds for a June 17 recommendation by advisory panel, analysts say.

FDA Notes Theoretical Cancer Risk For Centocor’s Ustekinumab

MAb for psoriasis has favorable odds for a June 17 recommendation by advisory panel, analysts say.

Europe Likes Schering’s Bridion, But Not Takeda’s Rozerem

New opinion includes CHMP skepticism of insomnia drug.

Related Content

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel